Literature DB >> 28688748

Congenital muscular dystrophies in the UK population: Clinical and molecular spectrum of a large cohort diagnosed over a 12-year period.

Maria Sframeli1, Anna Sarkozy2, Marta Bertoli3, Guja Astrea4, Judith Hudson3, Mariacristina Scoto2, Rachael Mein5, Michael Yau5, Rahul Phadke2, Lucy Feng2, Caroline Sewry2, Adeline Ngoh Seow Fen2, Cheryl Longman6, Gary McCullagh7, Volker Straub3, Stephanie Robb2, Adnan Manzur2, Kate Bushby3, Francesco Muntoni8.   

Abstract

Congenital muscular dystrophies (CMDs) are clinically and genetically heterogeneous conditions; some fatal in the first few years of life and with central nervous system involvement, whereas others present a milder course. We provide a comprehensive report of the relative frequency and clinical and genetic spectrum of CMD in the UK. Genetic analysis of CMD genes in the UK is centralised in London and Newcastle. Between 2001 and 2013, a genetically confirmed diagnosis of CMD was obtained for 249 unrelated individuals referred to these services. The most common CMD subtype was laminin-α2 related CMD (also known as MDC1A, 37.4%), followed by dystroglycanopathies (26.5%), Ullrich-CMD (15.7%), SEPN1 (11.65%) and LMNA (8.8%) gene related CMDs. The most common dystroglycanopathy phenotype was muscle-eye-brain-like disease. Fifteen patients carried mutations in the recently discovered ISPD, GMPPB and B3GALNT2 genes. Pathogenic allelic mutations in one of the CMD genes were also found in 169 unrelated patients with milder phenotypes, such as limb girdle muscular dystrophy and Bethlem myopathy. In all, we identified 362 mutations, 160 of which were novel. Our results provide one of the most comprehensive reports on genetics and clinical features of CMD subtypes and should help diagnosis and counselling of families with this group of conditions.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  B3GALTN2; COL6A1-A2-A3; Congenital muscular dystrophy; Dystroglycanopathies; GMPPB; ISPD; LAMA2; LMNA; Prevalence; SEPN1

Mesh:

Substances:

Year:  2017        PMID: 28688748     DOI: 10.1016/j.nmd.2017.06.008

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  19 in total

1.  Identification of mammalian glycoproteins with type-I LacdiNAc structures synthesized by the glycosyltransferase B3GALNT2.

Authors:  Takahiro Nakane; Kiyohiko Angata; Takashi Sato; Hiroyuki Kaji; Hisashi Narimatsu
Journal:  J Biol Chem       Date:  2019-03-21       Impact factor: 5.157

Review 2.  Laminin-deficient muscular dystrophy: Molecular pathogenesis and structural repair strategies.

Authors:  Peter D Yurchenco; Karen K McKee; Judith R Reinhard; Markus A Rüegg
Journal:  Matrix Biol       Date:  2017-11-27       Impact factor: 11.583

3.  Merosin deficient congenital muscular dystrophy type 1A: An international workshop on the road to therapy 15-17 November 2019, Maastricht, the Netherlands.

Authors:  Hubert J M Smeets; Bram Verbrugge; Pierre Springuel; Nicol C Voermans
Journal:  Neuromuscul Disord       Date:  2021-05-01       Impact factor: 4.296

4.  Association of Initial Maximal Motor Ability With Long-term Functional Outcome in Patients With COL6-Related Dystrophies.

Authors:  Daniel Natera-de Benito; A Reghan Foley; Cristina Domínguez-González; Carlos Ortez; Minal Jain; Aron Mebrahtu; Sandra Donkervoort; Ying Hu; Margaret Fink; Pomi Yun; Tracy Ogata; Julita Medina; Meritxell Vigo; Katherine G Meilleur; Meganne E Leach; Jahannaz Dastgir; Jordi Díaz-Manera; Laura Carrera-García; Jessica Expósito-Escudero; Macarena Alarcon; Daniel Cuadras; Elena Montiel-Morillo; José C Milisenda; Raul Dominguez-Rubio; Montse Olivé; Jaume Colomer; Cristina Jou; Cecilia Jimenez-Mallebrera; Carsten G Bönnemann; Andres Nascimento
Journal:  Neurology       Date:  2021-01-13       Impact factor: 9.910

5.  Laminin α2 controls mouse and human stem cell behaviour during midbrain dopaminergic neuron development.

Authors:  Maqsood Ahmed; Leandro N Marziali; Ernest Arenas; M Laura Feltri; Charles Ffrench-Constant
Journal:  Development       Date:  2019-08-29       Impact factor: 6.868

6.  The clinical, histologic, and genotypic spectrum of SEPN1-related myopathy: A case series.

Authors:  Rocio N Villar-Quiles; Maja von der Hagen; Corinne Métay; Victoria Gonzalez; Sandra Donkervoort; Enrico Bertini; Claudia Castiglioni; Denys Chaigne; Jaume Colomer; Maria Luz Cuadrado; Marianne de Visser; Isabelle Desguerre; Bruno Eymard; Nathalie Goemans; Angela Kaindl; Emmanuelle Lagrue; Jürg Lütschg; Edoardo Malfatti; Michèle Mayer; Luciano Merlini; David Orlikowski; Ulrike Reuner; Mustafa A Salih; Beate Schlotter-Weigel; Mechthild Stoetter; Volker Straub; Haluk Topaloglu; J Andoni Urtizberea; Anneke van der Kooi; Ekkehard Wilichowski; Norma B Romero; Michel Fardeau; Carsten G Bönnemann; Brigitte Estournet; Pascale Richard; Susana Quijano-Roy; Ulrike Schara; Ana Ferreiro
Journal:  Neurology       Date:  2020-08-13       Impact factor: 9.910

7.  Causative variant profile of collagen VI-related dystrophy in Japan.

Authors:  Michio Inoue; Yoshihiko Saito; Takahiro Yonekawa; Megumu Ogawa; Aritoshi Iida; Ichizo Nishino; Satoru Noguchi
Journal:  Orphanet J Rare Dis       Date:  2021-06-24       Impact factor: 4.123

8.  Utility of Immunohistochemistry and Western Blot in Profiling Clinically Suspected Cases of Congenital Muscular Dystrophy.

Authors:  Radhika Mhatre; Deepha Sekar; Jessiena Ponmalar; Madhu Nagappa; Preethish-Kumar Veeramani; Kiran Polavarapu; Seena Vengalil; Nalini Atchayaram; Gayathri Narayanappa
Journal:  Ann Indian Acad Neurol       Date:  2020-07-24       Impact factor: 1.383

Review 9.  At the Crossroads of Clinical and Preclinical Research for Muscular Dystrophy-Are We Closer to Effective Treatment for Patients?

Authors:  Kinga I Gawlik
Journal:  Int J Mol Sci       Date:  2018-05-16       Impact factor: 5.923

10.  Brain Dysfunction in LAMA2-Related Congenital Muscular Dystrophy: Lessons From Human Case Reports and Mouse Models.

Authors:  Andrea J Arreguin; Holly Colognato
Journal:  Front Mol Neurosci       Date:  2020-07-23       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.